La cadena de opciones muestra datos clave de las opciones de acciones de American Well a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para American Well..

American Well (NYSE:AMWL) Bolsa, Cadena de Opciones

American Well

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

American Well Corporation Class A Common Stock

American Well Corp

DA Davidson analyst Michael Shlisky maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Buy and lowers the price target from $120 to $111.

News

Price Target

Analyst Ratings

DA Davidson Maintains Buy on Oshkosh, Lowers Price Target to $111

Mizuho analyst Ben Chaiken maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Neutral and lowers the price target from $52 to $50.

Mizuho Maintains Neutral on Red Rock Resorts, Lowers Price Target to $50

Roth MKM analyst George Kelly reiterates Carriage Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSV#NYSE">CSV</a>) with a Buy and raises the price target from $48 to $51.

Reiteration

Roth MKM Reiterates Buy on Carriage Servs, Raises Price Target to $51

DA Davidson analyst Brent Thielman maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Neutral and raises the price target from $295 to $305.

DA Davidson Maintains Neutral on Quanta Services, Raises Price Target to $305

Roth MKM analyst Scott Stember reiterates Patrick Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) with a Buy and lowers the price target from $112 to $100.

PATK

Roth MKM Reiterates Buy on Patrick Industries, Lowers Price Target to $100

WIIM

RIOT

Riot Platforms shares are trading higher after the company reported better-than-expected Q1 sales results.

LMAT

LeMatire Vascular shares are trading lower after the company reported Q1 EPS guidance below estimates and lowered its FY25 EPS guidance.

In a world of increasingly divided markets between yield-hungry investors and adrenaline-seeking traders, Defiance ETFs is convinced there are some who want both. Meet the Defiance Leveraged Long + Income MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MST#NASDAQ">MST</a>), a recently introduced fund that combines leveraged long exposure to MicroStrategy Inc (Strategy) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock with an unusual twist in the <a href="https://www.benzinga.com/etfs">world of geared ETFs</a> — weekly income.
It&#8217;s a high-wire performance: part momentum game, part revenue driver and all constructed around one of Wall Street&#8217;s most unstable surrogates for Bitcoin.
Also Read: <a href="https://www.benzinga.com/25/05/45149385/new-grayscale-etf-lets-you-invest-in-bitcoin-without-the-coin">New Grayscale ETF Lets You Invest In Bitcoin, Without The Coin</a>
<h1 class="wp-block-heading">A First-of-Its-Kind Structure</h1>
MST is the inaugural ETF to provide 1.5x to 2x daily exposure to MicroStrategy (Strategy) while at the same time attempting to distribute income weekly through a credit call spread method. It&#8217;s a structural spin designed to calm the volatile wildness of leveraged investing with the promise of regular, options-based payouts.
The dual aim of the fund — long-term capital growth and income generation — demonstrates increasing demand among retail investors for products that provide more than a simple directional gamble.
But <a href="https://www.globenewswire.com/news-release/2025/05/02/3073048/0/en/Defiance-ETFs-Unveils-MST-The-First-Leveraged-MicroStrategy-ETF-that-Seeks-to-Pay-Income-Weekly.html">MST </a>is not exactly a low-risk proposition: the levered element sees dramatic MicroStrategy (Strategy) movements working both ways, and the fund&#8217;s performance can stray from the mark when markets are volatile.
MST itself holds no cryptocurrencies, but its underlying stock of MicroStrategy (Strategy) is nominally a Bitcoin exposure vehicle masquerading as such. With Chairman Michael Saylor at the helm, the company has amassed billions of Bitcoin and now marches in near-lockstep with crypto sentiment. 
That makes MST, for good or bad, a means of playing Bitcoin&#8217;s upside (and downside) without actually holding the asset.
The firm bets on its success with previous MSTR-tied funds, the Daily Target 2X Long MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTX#NASDAQ">MSTX</a>) and the Daily Target 2X Short MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMST#NASDAQ">SMST</a>), which collectively have grown more than $1 billion in assets. MST extends the firm further into its theme of democratizing thematic, tactical ETFs to retail investors — without dumbing down the complexity.
But this is no sleepy index fund. The options overlay and dynamic leverage of the fund mean that investors have to remain vigilant to both reward and risk. MST can produce income and leverage returns — but in volatile markets, it can also leverage losses.
MST provides an unorthodox combination of crypto-adjacent leverage and weekly income, designed for risk-willing investors seeking to straddle momentum and cash flow. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45153699/new-etf-bets-on-small-companies-to-offer-growth-monthly-income">New ETF Bets On Small Companies To Offer Growth, Monthly Income</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

New ETFs

ETFs

S&P Midcap 400 Index Capital Protected Notes 

MSTR

MSTX

SMST

New MST ETF Mixes MicroStrategy (Strategy) Leverage With A Side Of Weekly Income

Roth MKM analyst Philip Shen maintains FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) with a Neutral and raises the price target from $3 to $3.5.

FTCI

Roth MKM Maintains Neutral on FTC Solar, Raises Price Target to $3.5

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BHC#TSX">BHC</a>) with a Sector Perform and raises the price target from C$8.5 to C$10.

TSX:BHC

RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to C$10

Roth MKM analyst Rohit Kulkarni maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Neutral and raises the price target from $120 to $130.

RDDT

Roth MKM Maintains Neutral on Reddit, Raises Price Target to $130

Roth MKM analyst Jeff Martin maintains OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) with a Buy and raises the price target from $224 to $245.

OSIS

Roth MKM Maintains Buy on OSI Systems, Raises Price Target to $245

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) with a Sector Perform and raises the price target from $8.5 to $10.

RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10

Select Medical Holdings shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

Bain Capital Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCSF#NYSE">BCSF</a>) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Bain Capital Specialty to report an earnings per share (EPS) of $0.47.
Investors in Bain Capital Specialty are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 3.25% increase in the share price on the subsequent day.

<img src="https://www.benzinga.com/files/images/story/2025/1746205869_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bain Capital Specialty were trading at $15.01 as of May 01. Over the last 52-week period, shares are down 8.81%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Bain Capital Specialty</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Bain Capital Specialty.
With 4 analyst ratings, Bain Capital Specialty has a consensus rating of Neutral. The average one-year price target is $17.5, indicating a potential 16.59% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Virtus Inv, P10 and WisdomTree, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Underperform trajectory for Virtus Inv, with an average 1-year price target of $183.14, suggesting a potential 1120.12% upside.</li>
<li>Analysts currently favor an Outperform trajectory for P10, with an average 1-year price target of $14.0, suggesting a potential 6.73% downside.</li>
<li>Analysts currently favor an Sell trajectory for WisdomTree, with an average 1-year price target of $8.5, suggesting a potential 43.37% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Virtus Inv, P10 and WisdomTree are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acadian Asset Management</td>
<td>Neutral</td>
<td>27.90%</td>
<td>$91.70M</td>
<td>4047.62%</td>
</tr>
<tr>
<td>Virtus Inv</td>
<td>Underperform</td>
<td>-6.69%</td>
<td>$126.21M</td>
<td>3.20%</td>
</tr>
<tr>
<td>P10</td>
<td>Outperform</td>
<td>34.80%</td>
<td>$45.59M</td>
<td>1.51%</td>
</tr>
<tr>
<td>WisdomTree</td>
<td>Sell</td>
<td>21.85%</td>
<td>$57.81M</td>
<td>6.76%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Bain Capital Specialty ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>About Bain Capital Specialty</h3>
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
<h3>Breaking Down Bain Capital Specialty's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3 months period, Bain Capital Specialty faced challenges, resulting in a decline of approximately -23.91% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Bain Capital Specialty's net margin excels beyond industry benchmarks, reaching 81.64%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bain Capital Specialty's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.94%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.86%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bain Capital Specialty's debt-to-equity ratio is below the industry average at 1.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/BCSF/earnings">To track all earnings releases for Bain Capital Specialty visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BCSF

What's Next: Bain Capital Specialty's Earnings Preview

Roth MKM analyst Jason Wittes maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $405 to $456.

Roth MKM Maintains Buy on Stryker, Raises Price Target to $456

RBC Capital analyst Irene Nattel maintains Aritzia (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATZ#TSX">ATZ</a>) with a Outperform and raises the price target from C$65 to C$68.

TSX:ATZ

RBC Capital Maintains Outperform on Aritzia, Raises Price Target to C$68

Roth MKM analyst Eric Handler maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Neutral and raises the price target from $72 to $74.

RBLX

Roth MKM Maintains Neutral on Roblox, Raises Price Target to $74

Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares are trading lower on Friday after the company <a href="https://www.benzinga.com//node/45152693">issued guidance below estimates.</a>
What To Know: Roku expects second-quarter sales of $1.07 billion, versus the consensus estimate of $1.09 billion. Device revenue is expected to remain consistent with 2024 levels, but tariff-related impacts remain difficult to project.
For the full year, Roku cut its sales guidance to $4.55 billion, versus the consensus estimate of $4.57 billion. Furthermore, the company projected platform revenue to increase 14% year-over-year and device revenue to decline 10% year-over-year.
In the company&#8217;s letter to shareholders it said, &#8220;While there is more macro uncertainty than normal, we are providing our best outlook based on our current visibility and what we are observing in our business.&#8221;
Analyst Changes: Following the earnings report, multiple analysts lowered their price targets.
<ul>
<li>Rosenblatt analyst Barton Crockett maintained a Neutral rating on Roku and lowered the price target from&nbsp;$100&nbsp;to&nbsp;$75.</li>
<li>Evercore ISI Group analyst Shweta Khajuria maintained an In-Line rating on Roku and lowered the price target from&nbsp;$105&nbsp;to&nbsp;$80.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/25/05/45170457/100000-in-tuition-for-a-40000-salary-these-college-degrees-have-the-worst-financial-return">$100,000 In Tuition For A $40,000 Salary? These College Degrees Have The Worst Financial Return</a>
ROKU Price Action: At the time of writing, Roku shares are trading 6.36% lower at $62.99, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

ROKU

What's Going On With Roku Stock Friday?

Mastercard shares are trading higher. Keybanc maintained an Overweight rating on the stock and raised its price target from $630 to $635.

Press Releases

Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care

Amwell® to report fourth quarter and full year 2024 operating results

Amwell® Announces Results for Fourth Quarter and Full Year 2024

Amwell® to participate in upcoming investor conference

Amwell® makes grants to new employees under inducement plan

Health Care

Management

Amwell announces innovation leader as chief product and technology officer

Amwell makes inducement grant

Amwell® to report first quarter 2025 operating results

Amwell® to participate in upcoming investor conferences

Amwell® Announces Results for First Quarter 2025

AMWL

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

VSee Health

Waystar Holding

Stifel

Truist Securities

Wells Fargo

Morgan Stanley

American Well shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance with its midpoint above estimates.

Comments

American Well

American Well (AMWL) Opciones

American Well (NYSE:AMWL) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL